Supplementary Material for: Icosabutate, a Structurally Engineered Fatty Acid, Improves the Cardiovascular Risk Profile in Statin-Treated Patients with Residual Hypertriglyceridemia

  • John Kastelein (Contributor)
  • Jonas Hallén (Creator)
  • Runar Vige (Creator)
  • David A. Fraser (Creator)
  • Rong Zhou (Creator)
  • Svein Olaf Hustvedt (Creator)
  • David G. Orloff (Creator)
  • Harold E. Bays (Creator)
  • J. Hallén (Creator)

Dataset

Description

Objectives: To evaluate the efficacy and safety of icosabutate, an oral, once-daily, first-in-class medication, in reducing non-high-density lipoprotein cholesterol (non-HDL-C) in patients with persistent hypertriglyceridemia despite statin therapy. Met...
Date made available2016
PublisherKarger Publishers

Cite this